Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Budesonide/formoterol - Intech Biopharm

Next Previous
Drug Profile

Budesonide/formoterol - Intech Biopharm

Alternative Names: SYN 010; SYN010 HFA Inhaler

Latest Information Update: 31 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intech Biopharm
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 05 Aug 2020 Intech Biopharm completes the phase I trial in Asthma (In volunteers) and chronic-obstructive-pulmonary-disease (In volunteers) in Taiwan (Inhalation, Aerosol) (NCT04494321)
  • 28 Apr 2019 No recent reports of development identified for phase-I development in Asthma(In volunteers) in Taiwan (Inhalation, Aerosol)
  • 28 Apr 2019 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in Taiwan (Inhalation, Aerosol)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top